Handok (002390) - Net Assets
Based on the latest financial reports, Handok (002390) has net assets worth ₩278.32 Billion KRW (≈ $188.61 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩790.75 Billion ≈ $535.88 Million USD) and total liabilities (₩512.43 Billion ≈ $347.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Handok (002390) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩278.32 Billion |
| % of Total Assets | 35.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -27.52% |
| 10-Year Change | -3.78% |
| Growth Volatility | 7.06 |
Handok - Net Assets Trend (2011–2025)
This chart illustrates how Handok's net assets have evolved over time, based on quarterly financial data. See Handok liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Handok (2011–2025)
The table below shows the annual net assets of Handok from 2011 to 2025. For live valuation and market cap data, see Handok stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩278.32 Billion ≈ $188.61 Million |
-3.72% |
| 2024-12-31 | ₩289.06 Billion ≈ $195.89 Million |
-15.14% |
| 2023-12-31 | ₩340.63 Billion ≈ $230.84 Million |
-10.80% |
| 2022-12-31 | ₩381.86 Billion ≈ $258.78 Million |
-0.56% |
| 2021-12-31 | ₩384.00 Billion ≈ $260.23 Million |
+0.56% |
| 2020-12-31 | ₩381.85 Billion ≈ $258.77 Million |
+11.00% |
| 2019-12-31 | ₩343.99 Billion ≈ $233.12 Million |
+9.77% |
| 2018-12-31 | ₩313.38 Billion ≈ $212.37 Million |
+7.80% |
| 2017-12-31 | ₩290.71 Billion ≈ $197.01 Million |
+0.51% |
| 2016-12-31 | ₩289.25 Billion ≈ $196.02 Million |
-4.76% |
| 2015-12-31 | ₩303.71 Billion ≈ $205.82 Million |
-1.32% |
| 2014-12-31 | ₩307.77 Billion ≈ $208.57 Million |
+4.59% |
| 2013-12-31 | ₩294.28 Billion ≈ $199.43 Million |
+2.45% |
| 2012-12-31 | ₩287.25 Billion ≈ $194.67 Million |
+3.20% |
| 2011-12-31 | ₩278.34 Billion ≈ $188.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Handok's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22566666905000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩225.67 Billion | 81.58% |
| Other Components | ₩50.94 Billion | 18.42% |
| Total Equity | ₩276.61 Billion | 100.00% |
Handok Competitors by Market Cap
The table below lists competitors of Handok ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NPC Co. Ltd
KO:004250
|
$68.69 Million |
|
Hyundai E P
KO:089470
|
$68.72 Million |
|
Groupe LDLC SA
PA:ALLDL
|
$68.73 Million |
|
Dongnam Chem
KO:023450
|
$68.74 Million |
|
Big Ridge Gold Corp
V:BRAU
|
$68.67 Million |
|
RoboRobo Co. Ltd
KQ:215100
|
$68.64 Million |
|
CENIT Aktiengesellschaft
XETRA:CSH
|
$68.62 Million |
|
Xin Chio Global Co Ltd
TWO:3171
|
$68.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Handok's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 287,262,262,410 to 276,608,514,860, a change of -10,653,747,550 (-3.7%).
- Net loss of 2,153,006,030 reduced equity.
- Dividend payments of 2,752,706,600 reduced retained earnings.
- Share repurchases of 9,319,596,350 reduced equity.
- Other factors increased equity by 3,571,561,430.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.15 Billion | -0.78% |
| Dividends Paid | ₩2.75 Billion | -1.0% |
| Share Repurchases | ₩9.32 Billion | -3.37% |
| Other Changes | ₩3.57 Billion | +1.29% |
| Total Change | ₩- | -3.71% |
Book Value vs Market Value Analysis
This analysis compares Handok's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.37x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩22838.20 | ₩7800.00 | x |
| 2018-12-31 | ₩22572.56 | ₩7800.00 | x |
| 2019-12-31 | ₩24757.03 | ₩7800.00 | x |
| 2020-12-31 | ₩27703.50 | ₩7800.00 | x |
| 2021-12-31 | ₩27899.55 | ₩7800.00 | x |
| 2022-12-31 | ₩27595.57 | ₩7800.00 | x |
| 2023-12-31 | ₩24610.83 | ₩7800.00 | x |
| 2024-12-31 | ₩20871.26 | ₩7800.00 | x |
| 2025-12-31 | ₩21292.39 | ₩7800.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Handok utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.40%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 2.86x
- Recent ROE (-0.78%) is below the historical average (0.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 5.95% | 4.97% | 0.82x | 1.47x | ₩-11.26 Billion |
| 2012 | 2.01% | 1.83% | 0.72x | 1.52x | ₩-22.96 Billion |
| 2013 | 4.18% | 3.75% | 0.69x | 1.61x | ₩-17.12 Billion |
| 2014 | 0.48% | 0.42% | 0.68x | 1.67x | ₩-29.30 Billion |
| 2015 | -0.57% | -0.47% | 0.68x | 1.78x | ₩-31.53 Billion |
| 2016 | -2.30% | -1.63% | 0.64x | 2.22x | ₩-34.54 Billion |
| 2017 | 1.71% | 1.16% | 0.65x | 2.25x | ₩-23.56 Billion |
| 2018 | 2.60% | 1.79% | 0.68x | 2.12x | ₩-22.75 Billion |
| 2019 | 10.25% | 7.38% | 0.63x | 2.20x | ₩854.30 Million |
| 2020 | 7.07% | 5.35% | 0.61x | 2.15x | ₩-11.17 Billion |
| 2021 | 0.86% | 0.64% | 0.62x | 2.19x | ₩-35.10 Billion |
| 2022 | 2.81% | 1.96% | 0.62x | 2.29x | ₩-27.30 Billion |
| 2023 | -8.50% | -5.51% | 0.66x | 2.33x | ₩-62.67 Billion |
| 2024 | -18.30% | -10.36% | 0.64x | 2.75x | ₩-81.29 Billion |
| 2025 | -0.78% | -0.40% | 0.68x | 2.86x | ₩-29.81 Billion |
Industry Comparison
This section compares Handok's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $329,362,045,253
- Average return on equity (ROE) among peers: 3.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Handok (002390) | ₩278.32 Billion | 5.95% | 1.84x | $68.67 Million |
| Dongwha Pharm.Co.Ltd (000020) | $297.40 Billion | 3.39% | 0.25x | $97.49 Million |
| Yuhan Corp. (000100) | $519.03 Billion | 9.81% | 0.47x | $3.90 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 3.48% | 0.32x | $51.83 Million |
| Yuyu Pharma (000220) | $128.69 Billion | -1.72% | 0.50x | $43.48 Million |
| Yuyu Pharma Inc (000225) | $120.36 Billion | -5.97% | 0.65x | $14.47 Million |
| Yuyu Pharma Inc (000227) | $86.87 Billion | 4.63% | 0.56x | $42.09 Million |
| Ildong Holdings Co Ltd (000230) | $55.81 Billion | 8.24% | 2.38x | $53.57 Million |
| Samil Pharm (000520) | $54.41 Billion | 1.08% | 0.83x | $101.43 Million |
| Donga Socio Holdings (000640) | $266.72 Billion | 7.48% | 1.59x | $367.37 Million |
| Jw Pharmac (001060) | $112.60 Billion | 9.51% | 2.66x | $416.42 Million |
About Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more